^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lymphoma
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    thiotepa (DNA synthesis inhibitor, Alkylating agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    PRIMARY CNS LYMPHOMA….Preferred Regimens...High-dose systemic therapy with stem cell rescue...Cytarabine + thiotepa followed by carmustine + thiotepa
    Secondary therapy:
    TT-BCNU